Management of Alcohol Dependence in Patients with Liver Disease
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Alcohol dependence represents a chronic and relapsing disease affecting nearly 10 % of the general population both in the USA and in Europe, with a widespread burden of morbidity and mortality. Alcohol dependence represents the most common cause of liver damage in the Western world. Although alcoholic liver disease is associated primarily with heavy drinking, continued alcohol consumption, even in low doses after the onset of liver disease, increases the risk of severe consequences, including mortality. Consequently, the ideal treatment of patients affected by alcohol dependence and alcoholic liver disease should aim at achieving long-term total alcohol abstinence and preventing relapse. The aim of the present review is to provide an update on the management of alcohol dependence in patients with alcoholic liver disease. Increasing evidence suggests the usefulness of psychosocial interventions and medications combined in order to reduce alcohol intake, promote abstinence and prevent relapse in alcohol-dependent patients. Disulfiram, naltrexone and acamprosate have been approved for this indication; gamma-hydroxybutyric acid (GHB) is approved in Italy and Austria. However, these drugs have not been tested in patients with advanced liver disease. Amongst other emerging pharmacotherapies for alcoholism, topiramate, ondansetron, and baclofen seem the most promising ones. Both topiramate and ondansetron have a safe profile in alcoholic patients; however, none of them has been tested in alcoholic patients with advanced liver disease. To date, baclofen represents the only anti-craving medication formally tested in a randomized clinical trial in alcoholic patients affected by liver cirrhosis, although additional confirmatory studies are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597 · cited 5×
“A total score of more than 8 indicates harmful drinking behavior, while a total score of more than 13 in women and 15 in men indicates likely AD.”
InfluentialActual causes of death in the United States
McGinnis, J. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510180077038 · Cited by 5,480
Kessler, R. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830160031005 · Cited by 2,085
(1997) · Journal of Studies on Alcohol · doi:10.15288/jsa.1997.58.7 · Cited by 1,905
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.04.004 · Cited by 720
Drinking habits as cofactors of risk for alcohol induced liver damage
Bellentani, S., Saccoccio, G., Costa, G., Tiribelli, C., Manenti, F., Sodde, M., Croce’, L. S., Sasso, F., Pozzato, G., Cristianini, G., et al. (1997) · Gut · doi:10.1136/gut.41.6.845 · Cited by 630 · cited 1×
“Data from the “Dionysos” study showed that consumption of more than about two drinks per day increases the risk of liver disease regardless of the gender.[24] ALD, one of the major medical complications of AUDs,[25] represents a wide spectrum of diseases including simple steatosis, alcoholic steatohepatitis (ASH), pro…”
BackgroundNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571
Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451 · cited 1×
“High levels of craving, a positive family history of alcoholism [41] and the presence of a specific polymorphism (Asn40Asp) in the mu opioid receptor gene [59, 60], have been shown to be predictors of a positive response to naltrexone.”
BackgroundDisulfiram Treatment of Alcoholism: A Veterans Administration Cooperative Study
Fuller, R. K. (1986) · JAMA · doi:10.1001/jama.1986.03380110055026 · Cited by 431 · cited 1×
“multivitamin),[47] other studies showed that patients who receive disulfiram report more total days of abstinence from alcohol as well as lower levels of GGT, which is the objective marker of alcohol consumption, when compared to placebo groups.”
BackgroundDrug therapy for alcohol dependence
Swift, R. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401907 · Cited by 255 · cited 1×
“These pathways include several neurotransmitters, such as gamma-aminobutyric acid (GABA), glutamate, opioids, dopamine (DA), serotonin, adenosine, neuropeptide Y, norepinephrine, acetylcholine and cannabinoids.[14] Furthermore, different subtypes of patients could have different and/or several mechanisms craving is ba…”
BackgroundNeuroprotective and Abstinence-Promoting Effects of Acamprosate: Elucidating the Mechanism of Action
De Witte, P., Littleton, J., Parot, P., & Koob, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519060-00004 · Cited by 201 · cited 1×
“A glutamatergic antagonist and GABA agonist, it is thought to normalize the glutamatergic excitation that occurs during alcohol withdrawal.[63] European large clinical trials resulted in strong effect sizes for improving drinking outcomes.”
BackgroundGamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses
Leone, M. A., Vigna-Taglianti, F., Avanzi, G., Brambilla, R., & Faggiano, F. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006266.pub2 · Cited by 163
Cited by
Pathophysiological Aspects of Alcohol Metabolism in the Liver
Hyun, J., Han, J., Lee, C., Yoon, M., & Jung, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115717 · Cited by 324
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh, S., Osna, N. A., & Kharbanda, K. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6549 · Cited by 257
Addolorato, G., Mirijello, A., Leggio, L., Ferrulli, A., D'Angelo, C., Vassallo, G., Cossari, A., Gasbarrini, G., Landolfi, R., Agnes, S., et al. (2013) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12117 · Cited by 203
“When even total alcohol abstinence does not result in a significant improvement of liver function, orthotopic liver transplantation (OLT) represents the gold standard treatment for end-stage alcoholic liver disease (Varma et al., 2010; Addolorato et al., 2013).”
BackgroundSelf-citationBrain-wide functional architecture remodeling by alcohol dependence and abstinence
Kimbrough, A., Lurie, D. J., Collazo, A., Kreifeldt, M., Sidhu, H., Macedo, G. C., D’Esposito, M., Contet, C., & George, O. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909915117 · Cited by 97
Pharmacotherapy for alcoholic patients with alcoholic liver disease
Vuittonet, C. L., Halse, M., Leggio, L., Fricchione, S. B., Brickley, M., Haass-Koffler, C. L., Tavares, T., Swift, R. M., & Kenna, G. A. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140028 · Cited by 51
Self-citation
Metadata
- Authors
- Addolorato, G., Mirijello, A., Leggio, L., Ferrulli, A., & Landolfi, R.
- Venue
- CNS Drugs
- Published
- 2013-03-01
- Volume
- 27
- Issue
- 4
- Pages
- 287-299
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2077335179
- Cited by
- 110
- References
- 16
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.